EP3788062A4 - Methods of diagnosing and treating based on site-specific tau phosphorylation - Google Patents

Methods of diagnosing and treating based on site-specific tau phosphorylation Download PDF

Info

Publication number
EP3788062A4
EP3788062A4 EP19797038.7A EP19797038A EP3788062A4 EP 3788062 A4 EP3788062 A4 EP 3788062A4 EP 19797038 A EP19797038 A EP 19797038A EP 3788062 A4 EP3788062 A4 EP 3788062A4
Authority
EP
European Patent Office
Prior art keywords
diagnosing
site
methods
tau phosphorylation
specific tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19797038.7A
Other languages
German (de)
French (fr)
Other versions
EP3788062A1 (en
Inventor
Nicolas BARTHELEMY
Randall John Bateman
Eric MCDADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of EP3788062A1 publication Critical patent/EP3788062A1/en
Publication of EP3788062A4 publication Critical patent/EP3788062A4/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
EP19797038.7A 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation Pending EP3788062A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666509P 2018-05-03 2018-05-03
US201862666504P 2018-05-03 2018-05-03
PCT/US2019/030725 WO2019213612A1 (en) 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation

Publications (2)

Publication Number Publication Date
EP3788062A1 EP3788062A1 (en) 2021-03-10
EP3788062A4 true EP3788062A4 (en) 2022-02-16

Family

ID=68386729

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19797038.7A Pending EP3788062A4 (en) 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation

Country Status (11)

Country Link
EP (1) EP3788062A4 (en)
JP (1) JP7301394B2 (en)
KR (1) KR20210004996A (en)
CN (1) CN112166117A (en)
AU (1) AU2019262220A1 (en)
BR (1) BR112020021782A2 (en)
CA (1) CA3097667A1 (en)
MX (1) MX2020011458A (en)
SG (1) SG11202010094TA (en)
WO (1) WO2019213612A1 (en)
ZA (1) ZA202006348B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017006419A2 (en) 2014-09-30 2017-12-19 Univ Washington kinetic measurements of tau
WO2021030615A1 (en) * 2019-08-13 2021-02-18 Washington University Methods to detect mtbr tau isoforms and use thereof
BR112022004326A2 (en) * 2019-09-10 2022-08-23 Univ Washington BLOOD BASED ASSAY FOR DIAGNOSIS AND TREATMENT BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
WO2021202777A1 (en) * 2020-04-01 2021-10-07 Genentech, Inc. Uses of tau phosphosites as biomarkers for alzheimer's disease
CA3203308A1 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN112763636B (en) * 2020-12-07 2022-04-19 佛山汉腾生物科技有限公司 Peptide map analysis method
EP4314841A1 (en) * 2021-03-31 2024-02-07 Washington University Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
US20240329050A1 (en) * 2021-07-16 2024-10-03 Washington University Methods of detecting pentasaccharides and treatment and monitoring of lysosomal storage disease
WO2023068173A1 (en) * 2021-10-18 2023-04-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 BIOMARKER FOR EVALUATING INTRACEREBRAL AMYLOID-β ACCUMULATION
KR20240002809A (en) * 2022-06-30 2024-01-08 광주과학기술원 Method for Early Diagnosis and Staging of Alzheimer's Disease and Screening Cerebral Amyloid Deposition Using Phosphorylated Peptide Derived from Tau Protein
KR20240002810A (en) * 2022-06-30 2024-01-08 광주과학기술원 Method for Early Diagnosis and Staging of Alzheimer's Disease and Screening Cerebral Amyloid Deposition Using Phosphorylated Peptide Derived from Alzheimer's Disease Related Protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101124247B (en) * 2004-07-30 2013-07-31 礼纳特神经系统科学公司 Antibodies directed against amyloid-beta peptide and uses thereof
WO2010011506A2 (en) * 2008-07-23 2010-01-28 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
FR2963791B1 (en) 2010-08-11 2012-09-21 Assist Publ Hopitaux De Paris METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES
PT2758433T (en) * 2011-09-19 2018-01-19 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CA2850686C (en) * 2011-10-07 2020-09-08 Ac Immune S.A. Phosphospecific antibodies recognising tau
EP2787349A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
TWI708058B (en) 2013-10-24 2020-10-21 美商納諾索米克斯公司 Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
RS61431B1 (en) * 2014-11-19 2021-03-31 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
WO2017053739A1 (en) * 2015-09-25 2017-03-30 Steen Judith Methods and compositions for tauopathy diagnosis and treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARTHÉLEMY N.R. ET AL.: "A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease", NATURE MED., vol. 26, no. 3, March 2020 (2020-03-01), pages 398 - 407, XP037060283 *
BARTHÉLEMY N.R. ET AL.: "Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-beta pathology", BIORXIV, 30 November 2017 (2017-11-30), pages 1 - 20, XP055621444, Retrieved from the Internet <URL:https://www.biorxiv.org/content/biorxiv/early/2017/11/30/226977.full.pdf> DOI: 10.1101/226977 *
BARTHÉLEMY N.R. ET AL.: "Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer's disease", FRONTIERS IN AGING NEUROSCIENCE, vol. 11, 121, 21 May 2019 (2019-05-21), pages 1 - 18, XP055717185 *
MAIR W. ET AL.: "FLEXITau: Quantifying post-translational modifications of tau protein in vitro and in human disease", ANAL. CHEM., vol. 88, no. 7, 5 April 2016 (2016-04-05), pages 3704 - 3714, XP055371662 *
RUSSELL C.L. ET AL.: "Comprehensive quantitative profiling of tau and phosphorylated tau peptides in cerebrospinal fluid by mass spectrometry provides new biomarker candidates", J. ALZHEIMER'S DIS., vol. 55, no. 1, 1 November 2016 (2016-11-01), pages 303 - 313, XP055865569 *
See also references of WO2019213612A1 *

Also Published As

Publication number Publication date
CN112166117A (en) 2021-01-01
JP7301394B2 (en) 2023-07-03
EP3788062A1 (en) 2021-03-10
CA3097667A1 (en) 2019-11-07
MX2020011458A (en) 2020-12-07
SG11202010094TA (en) 2020-11-27
KR20210004996A (en) 2021-01-13
JP2021523357A (en) 2021-09-02
WO2019213612A1 (en) 2019-11-07
ZA202006348B (en) 2022-01-26
AU2019262220A1 (en) 2020-11-12
AU2019262220A8 (en) 2020-12-10
BR112020021782A2 (en) 2021-02-23

Similar Documents

Publication Publication Date Title
EP3788062A4 (en) Methods of diagnosing and treating based on site-specific tau phosphorylation
EP3836859A4 (en) Systems and methods for affecting cardiac contractility and/or relaxation
EP3688465A4 (en) Diagnostic test system and method
SG11202005592QA (en) Financing Methods and Apparatuses
EP3719678A4 (en) Identity verification method and apparatus
EP3649608A4 (en) Systems and methods for verification of income
EP3665858A4 (en) Verification of interactions system and method
EP3805726A4 (en) Inspection system and inspection method
EP3644152A4 (en) Process abnormal state diagnosing device and abnormal state diagnosing method
EP3564658A4 (en) Security inspection system and method
EP3776465A4 (en) System of vehicle inspection and method thereof
EP3829439A4 (en) Systems and methods for treating memory impairment
EP3767560A4 (en) Future state estimation device and future state estimation method
EP3761133A4 (en) Diagnosis device and diagnosis method
EP3831553A4 (en) Abnormality determination device and abnormality determination method
EP3829444A4 (en) Improved imaging systems and methods
EP3789086A4 (en) Radiotherapy device and treatment method which uses device
EP3571310A4 (en) Compositions and methods for diagnosing and treating peroxisomal diseases
EP3685254A4 (en) Electronic apparatus and operating method of the same
EP3867635A4 (en) Diagnostic systems and methods
EP3740862A4 (en) Cryptographic systems and methods for modification of pools of truly random numbers
EP3719516A4 (en) Charging device test system and method
EP3573636A4 (en) Neurotrophin mutants for treating hearing loss and other otic disorders
EP3889570A4 (en) Vehicle testing system and vehicle testing method
IL291169A (en) Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038465

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0014470000

Ipc: G01N0033680000

A4 Supplementary search report drawn up and despatched

Effective date: 20220117

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101ALI20220111BHEP

Ipc: A61P 25/28 20060101ALI20220111BHEP

Ipc: A61K 39/395 20060101ALI20220111BHEP

Ipc: G01N 33/68 20060101AFI20220111BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230607